Saturday 17 October 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
98.06
4.67
−4.55%
Follow BLLN
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
1,320.00 | 0.00 | 0.00 |
P/S ratio |
4.26 | 4.59 | 4.59 |
Altman Z-Score |
6.04 | — | — |
Altman Z″-Score (non-manufacturers) |
7.37 | (0.24) | — |
P/FCF ratio |
82.68 | 0.00 | 0.00 |
Beneish M-Score |
(2.03) | — | — |
P/Operating CF |
120.39 | 113.67 | 113.67 |
P/B ratio |
2.71 | 0.00 | 0.00 |
Price to Tangible BV |
2.71 | 0.00 | 0.00 |
EV/Sales |
2.82 | 4.03 | 4.03 |
EV/EBITDA |
30.82 | 497.25 | 497.25 |
EV/Operating CF |
35.00 | 185.22 | 185.22 |
EV/FCF |
54.78 | (246.78) | (246.78) |
Quick Ratio |
11.21 | 7.62 | — |
Current Ratio |
11.69 | 8.03 | — |
Net Debt/EBITDA |
(15.70) | 3.96 | 0.00 |
Debt/Assets |
9.10% | 17.33% | 0.00% |
Debt/Equity |
0.12 | (0.21) | 0.00 |
Asset Turnover |
0.65 | 1.01 | 0.00 |
Operating CF/Net income |
8.43 | 1.00 | 0.65 |
Capex/Depreciation |
(0.75) | (0.45) | (0.88) |
Interest Coverage |
168.66 | (19.76) | (21.24) |
| 2.56% | 0.00% | 0.00% | |
| 0.62% | (27.52%) | 0.00% | |
ROIC |
24.01% | 0.00% | 0.00% |
Return on Tangible Assets |
0.55% | (19.20%) | 0.00% |
Average Days of Receivables |
49.79 | 59.11 | 0.00 |
Research and Development Expense of Revenue |
16.19% | 23.98% | 31.25% |
Selling, General and Administrative Expense of Revenue |
46.88% | 59.94% | 89.77% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.22% | 5.48% | 6.77% |
Graham Net Nets |
0.31 | (0.28) | (0.28) |
Graham Number |
6.50 | 0.00 | 0.00 |
Earnings Yield |
0.08% | (1.60%) | (1.60%) |
Free Cash Flow Yield |
1.21% | (0.36%) | (0.36%) |
Revenue per Share |
19.22 | 15.14 | 7.33 |
Operating CF per Share |
1.55 | (4.10) | (5.49) |
Capex per Share |
(0.56) | (0.54) | (0.63) |
Free Cash Flow per Share |
0.99 | (4.64) | (6.12) |
Cash per Share |
31.24 | 19.00 | 0.00 |
Shareholders Equity per Share |
30.24 | (24.97) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
30.24 | (24.97) | 0.00 |
Free Cash Flow |
15.71 | (46.78) | (59.85) |
Working Capital |
512.60 | 199.43 | — |
Capital Expenditures |
(8.88) | (5.40) | (6.17) |
Net Current Asset Value |
408.01 | (325.90) | 0.00 |
EV/EBIT |
53.72 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.04 | 0.09 |
Price to Operating Income |
81.08 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.58 | 0.70 | 0.00 |
Cash ROIC |
1.52% | 597.87% | 0.00% |
Accounts Receivable Turnover |
9.20 | 0.00 | 0.00 |
Accounts Payable Turnover |
16.83 | 0.00 | 0.00 |
Inventory Turnover |
7.36 | 0.00 | 0.00 |
Average Days of Payables |
27.13 | 21.92 | 0.00 |
Days of Inventory on Hand |
66.26 | 44.48 | 0.00 |
Average Receivables |
33.16 | — | — |
Average Payables |
5.74 | — | — |
Average Inventory |
13.14 | — | — |
Average Assets |
467.36 | 151.03 | — |
Average Common Equity |
114.22 | — | — |
Columns are period end dates